Teratogenic activity of HDAC inhibitors

Current Pharmaceutical Design

Volumn 20, Issue 34, 2014, Pages 5438-5442

  Giavini, Erminio ^a   Menegola, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Congenital malformations; HDAC inhibitors; Mechanisms; Teratogenesis

Indexed keywords

APICIDIN; BORIC ACID; BUTYRIC ACID; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; RETINOIC ACID; SALICYLIC ACID; TERATOGENIC AGENT; TRICHOSTATIN A; VALPROIC ACID;

ARTICLE; CELL DEATH; CHROMATIN STRUCTURE; CONGENITAL MALFORMATION; DEMETHYLATION; DEVELOPMENTAL DISORDER; DNA DAMAGE; EMBRYO DEVELOPMENT; HISTONE ACETYLATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TERATOGENESIS; TERATOGENICITY; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; METABOLISM; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE;

ANIMALS; CELL DEATH; CELL PROLIFERATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 84925844825     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140205144900     Document Type: Article

References (83)

1. [1] Inche AG, La Thangue NB. Chromatin control and acne-drug discovery: realizing the promise. Drug Discov Today 2006; 11: 97-109
2. [2] Spotswood HT, Turner BM. An increasingly complex code. J Clin Invest 2002; 110: 577-82
3. [3] Thiagalingam S. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad Sc 2003; 983: 84-100.
4. [4] Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of nonhistone proteins. Gene 2005; 363: 15-23.
5. [5] Lagger G, O’Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21: 2672-81.
6. [6] Xiang-Jiao Yang, Serge Grégoire. Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication. Mol Cellular Biol 2005; 25: 2873-84.
7. [7] Karrune V Woan, Eva Sahakian, Eduardo M Sotomayor, Edward Seto and Alejandro Villagra Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 2012; 90: 55-65
8. [8] Vega RB, Matsuda K, Oh J, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004; 119: 555-66.
9. [9] Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110: 479-88.
10. [10] Coverdale LE, Gaytry D, Cristofre M. Histone deacetylase 1 (HDAC-1) required for the normal formation of craniofacial cartilage and pectoral fins of the zebrafish. Dev Dynamics 2004; 231: 647-54.
11. [11] Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26: 5541-2.
12. [12] Johnston RW, Licht JD. Histone deacetylase inhibitors in cancer terapy: is transcription the primary target? Cancer Cell 2003; 4: 13-8
13. [13] Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor ms-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21cip1/waf1 1. Cancer Res 2003; 63: 3637-45.
14. [14] Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors, Adv Cancer Res 2004; 91: 137-68.
15. [15] Shao Y, Gao Z, Marks PA, et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-5.
16. [16] Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010; 19: 1049-166.
17. [17] Khan M, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
18. [18] Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2: 937.
19. [19] Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf 2005; 4: 345-53.
20. [20] Di Liberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473-81.
21. [21] Menegola E, Broccia ML, Nau H, et al. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Terat Carcin Mutag 1996; 16: 97-108
22. [22] Okada A, Kurihara H, Aoki Y, Bialer M, Fijiwara M. Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defects Res B 2004; 71: 47-53
23. [23] Ehlers K, Surje H, Merker HJ, Nau H. Valproic acid induced spina bifida: a mouse model. Teratology 1992; 45: 145-54
24. [24] Binkerd PE, Rowland JM, Nau H, Hendrickx AG. Evaluation of valproic acid developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fund Appl Toxicol 1988, 11: 485-93.
25. [25] Hendrickx AG, Nau H, Binkerd P, et al. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison. Teratology 1988; 38: 329-45.
26. [26] Kao J, Brown N, Schmid B, Goulding E, Fabro S. Teratogenicity of valproic acid: in vivo and in vitro investigations. Terat Carcin Mutag 1981; 1: 367-82.
27. [27] Petrere JA, Anderson JA, Sakowski R, et al. Teratogenesis of calcium valproate in rabbits. Teratology 1986; 34: 263-9.
28. [28] Vorhees CV. Teratogenicity and developmental toxicity of valproic acid in rats. Teratology 1987; 35: 195-202.
29. [29] Menegola E, Broccia ML, Prati M, Giavini E. Stage dependent skeletal malformations induced by valproic acid in rats. Int J Dev Biol 1998; 42: 99-102.
30. [30] Pile LA, Lee FW, Wassarman DA. The histone deacetylase inhibitor trichostatin A influences the development of Drosophila melanogaster. Cell Mol Life Sci 2001; 58: 1715-1718.
31. [31] Ikegami S, Ooe Y, Shimizu T, et al. Accumulation of multiacetylated forms of histones by trichostatin A and its developmental consequences in early starfish embryos. Roux’s Arch Dev Biol 1993; 202: 144-151.
32. [32] Nemer M. Histone deacetylase mRNA temporally and spatially regulated in its expression in sea urchin embryos. Dev Growth Differ 1998; 40: 583-90.
33. [33] Almouzni G, Khochbin S, Dimitrov S, et al. Histone acetylation influences both gene expression and development of Xenopus laevis. Dev Biol 1994; 165: 654-69.
34. [34] Sachs LM, Amano T, Rouse N, et al. Involvement of histone deacetylase at two distinct steps in gene regulation during intestinal development in Xenopus laevis. Dev Dyn 2001; 222: 280-91.
35. [35] Sachs LM, Amano T, Shi YB. An essential role of histone deacetylase in postembryonic organ transformations in Xenopus laevis. Int J Mol Med 2001; 8: 595-601.
36. [36] Gurvich N, Berman MG, Wittner BS, et al. Association of valproate induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005; 19: 1166-8.
37. [37] Nervi C, Borello U, Fazi F, et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res 2001; 61: 1247-9.
38. [38] Menegola E, Di Renzo F, Broccia ML, et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 2005; 74: 392-8.
39. [39] Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
40. [40] Di Renzo F, Broccia ML, Giavini E, Menegola E. Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mouse exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate. Toxicol Sci 2007; 98, 582-8.
41. [41] Wéry N, Foulon O, Blacker A, Picard JJ, Gofflot F. Vertebral malformations induced by sodium salicylate correlate with shifts in expression domains of Hox genes. Reprod Toxicol 2005; 20: 39-45.
42. [42] Wéry N, Narotsky MG, Pacico N, Kavlock RJ, Picard JJ, Gofflot F. Defects in cervical vertebrae in boric acid-exposed rat embryos are associated with anterior shifts of hox gene expression domains. Birth Defects Res A 2003; 67: 59-67.
43. [43] Di Renzo F, Cappelletti G, Broccia ML, Giavini E, Menegola E. Boric acid inhibits embryonic histone deacetylases: A suggested mechanism to explain boric acid-related teratogenicity. Toxicol ApplPharmacol 2007; 220: 178-85.
44. [44] Di Renzo F, Cappelletti G, Broccia ML, Giavini E, Menegola E. The inhibition of embryonic histone deacetylases as the possible mechanism accounting for axial skeletal malformations induced by sodium salicylate. Toxicol Sci 2008; 104: 397-404
45. [45] Barranco WT, Eckhert CD. Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 2006; 94, 884-90.
46. [46] Paterson JR, Lawrence JR.: Salicylic acid: A link between aspirin, diet and the prevention of colorectal cancer. Q J Med 2001; 94: 445-8.
47. [47] Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608-15.
48. [48] Jentik J, Dolk H, Loane MA, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systemic review and case-control study. B Med J 2010, 341: c6581
49. [49] Hunt S, Russell A, Smithson H, et al. Topiramate in pregnancy. Preliminary experience from the UK epilepsy and pregnancy register. Neurology 2008; 71: 272-6.
50. [50] Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Irelend epilepsy and pregnancy registers. Neurology 2013, 80: 400-5.
51. [51] Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-44.
52. [52] Beutler AS, Li S, Nicol R, Walsh MJ. Carbamazepine is an inhibitor of histone deacetylases. Life Sciences 2005; 76: 3107-15
53. [53] Wu G, Nan C, Rollo JC, Huang X, Tian J. Sodium valproateinduced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. J Biomed Sci 2010; 17: 16-23.
54. [54] Di Renzo F, Broccia ML, Giavini E, Menegola E. VPA-related axial skeletal defects and apoptosis: a proposed event cascade. Reprod Toxicol 2010; 29: 106-12.
55. [55] Marks PA. Dokmanovic MHistone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14: 1497-511.
56. [56] Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84
57. [57] Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in Pglycoprotein-expressing cells. Int J Cancer 2002; 99: 292-8
58. [58] Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006, 103: 15540-5.
59. [59] Lillig CH, Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 2007; 9: 25-47.
60. [60] Harris C and Hansen JC. Oxidative stress, thiols, and redox profiles. Methods Mol Biol 2012; 889: 325-46.
61. [61] Zhang B, Wang X, Nazarali AJ. Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis inmouseembryos in culture. Cell Mol Neurobiol 2010; 30: 137-48.
62. [62] Al Deeb S, Al Moutaery K, Arshaduddin M, Tariq M. Vitamin E decreases valproic acid induced neural tube defects in mice. Neuroscience Lett 2000; 292: 179-82.
63. [63] Tung EW, Winn LM. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol 2011; 80: 979-87.
64. [64] Schulpis KH, Lazaropoulou C, Regoutas S, et al. Valproic acid monotherapy induces DNA oxidative damage. Toxicology 2006; 217: 228-32.
65. [65] Varoglu AO, Yildirim A, Aygul R, Gundogdu OL, Sahin YN. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clinical Neuropharmacol 2010; 33: 155-7.
66. [66] Detich N, Bovenzi V, Szyf M. Valproate induces replicationindependent active DNA demethylation. J Biol Chem 2003; 278: 27586-92.
67. [67] Milutinovic S, D’Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007; 28: 560-71.
68. [68] Ou JN, Torrisani J, Unterberger A, et al N, Histone deacetylase inhibitor trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007; 73: 1297-307.
69. [69] Szyf M, Kaplan F, Mann V, Giloh H, Kedar E, Razin A. Cell cycle-dependent regulation of eukaryotic DNA methylase level. J Biol Chem 1985; 260: 8653-6.
70. [70] Brunaud L, Alberto JM, Ayav A, et al. Effects of vitamin B12 and folate deficiencies on DNA methylation and carcinogenesis in rat liver. Clin Chem Lab Med 2003; 41: 1012-9.
71. [71] De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N E J Med 2007; 357: 135-42.
72. [72] Persaud VL, Van den Hof MC, Dube JM, Zimmer P. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. Can Med Ass J 2002; 167: 241-5.
73. [73] Craig J, Morrison P, Morrow J, Patterson V. Failure of periconceptional folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999; 8: 253-4.
74. [74] Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia 2003; 44(Suppl. 3): 33-40.
75. [75] Pittschieler S, Brezinka C, Jahn B, Trinka E, et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol 2008; 255: 1926-31.
76. [76] Padmanabhan R, Shafiullah MM. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenital Anomalies 2003; 43: 29-40.
77. [77] Dawson JE, Raymond AM, Winn LM. Folic acid and pantothenic acid protection against valproic acid-induced neural tube defects in CD-1 mice. Toxicol App Pharmacol 2006; 211: 124-32.
78. [78] Hansen DK, Grafton TF, Dial SL, Gehring TA, Siitonen PH. Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. Teratology 1995; 52: 277-85.
79. [79] Bennett GD, Ridge L, Finnell RH. Folate, vitamin B12, inositol or pantothenic acid supplementation exacerbates the frequency of valproic acid induced neural tube defects. Toxicologist 1998; 42: 262.
80. [80] Kessel M, Gruss P. Homeotic transformations of murine vertebrae and concomitant alteration of hox codes induced by retinoic acid. Cell 1991, 67: 89-104.
81. [81] Kessel M. Respecification of vertebral identities by retinoic acid. Development 1992, 115: 487-501.
82. [82] Chuang CM, Chang CH, Wang HE, et al. Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis. A kinetic analysis on retinol/retinoic acid homeostatic system. PLOS ONE 2012, 7: e43692.
83. [83] Lee LMY, Leung CY, Tang WWC, et al A paradoxical teratogenic mechanism for retinoic acid. PNAS 2012, 109: 13668-73.